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Abstract Hypertrophic cardiomyopathy (HCM) is the most
common genetic heart disease, characterised by complex
pathophysiology and extensive genetic and clinical hetero-
geneity. In most patients, HCM is caused by mutations in
cardiac sarcomere protein genes and inherited as an auto-
somal dominant trait. The clinical phenotype ranges from
severe presentations at a young age to lack of left ventricular
hypertrophy in genotype-positive individuals. No preventa-
tive treatment is available as the sequence and causality of
the pathomechanisms that initiate and exacerbate HCM are
unknown. Sudden cardiac death and end-stage heart failure
are devastating expressions of this disease. Contemporary
management including surgical myectomy and implantable
cardiac defibrillators has shown significant impact on long-
term prognosis. However, timely recognition of specific sce-
narios – including transition to the end-stage phase – may
be challenging due to limited awareness of the progres-
sion patterns of HCM. This in turn may lead to missed
therapeutic opportunities. To illustrate these difficulties, we
describe two HCM patients who progressed from the typ-
ical hyperdynamic stage of asymmetric septal thickening
to end-stage heart failure with severely reduced ejection
fraction. We highlight the different stages of this complex
inherited cardiomyopathy based on the clinical staging pro-
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posed by Olivotto and colleagues. In this way, we aim to
provide a practical guide for clinicians and hope to increase
awareness for this common form of cardiac disease.
Keywords Hypertrophic cardiomyopathy · Diagnosis ·
Imaging
Introduction
Hypertrophic cardiomyopathy (HCM) is defined by in-
creased left ventricular (LV) wall thickness that is not
solely explained by abnormal loading conditions [1, 2]. It
is a cause of sudden cardiac death (SCD) at young age
and progression to end-stage heart failure (HF) is a feared
complication [1]. Disease onset generally ranges between
20–50 years of age, thus affecting patients in the prime
of their life. Until recently, HCM patients have been con-
sidered a sort of cardiological curiosity, ‘as rare as white
ravens’. Although the first mutation was identified as early
as 1989, thus paving the way for the molecular diagnosis
of HCM, society may still be relatively unaware of the true
burden of HCM [3]. Community-based echocardiographic
studies have consistently reported a 1:500 prevalence of
HCM worldwide, while Semsarian and colleagues re-
cently argued that a genetic diagnosis might be even more
common with an estimated prevalence of 1:200 [4]. This
high prevalence may be partly explained by the identifi-
cation of new sequence variants which may or may not
be pathogenic. The advances and limitations of genetic
screening in HCM were recently discussed by Ho and
colleagues [3]. Though great care must be taken in the
adjudication of pathogenicity for new variants, large-scale
implementation of affordable genetic screening [3, 4] has
led to increasing numbers of identified genotype-positive/
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Fig. 1 a Stages of hypertrophic
cardiomyopathy (adapted from
[4]) and clinical characteristics.
Mutation carriers (genotype
positive/phenotype negative,
G+/Ph–) may develop HCM
(i. e. move to stage II) or re-
main without cardiac symptoms
throughout their life (i. e. stable
G+/Ph–). b Studies in mouse
models and human cardiac sam-
ples revealed cellular changes
which may be target for ther-
apy to prevent onset of HCM
(LVOTO Left ventricular outflow
obstruction, LVEF LV ejec-
tion fraction, LA Left atrial,
LGE Late gadolinium enhance-
ment, AF Atrial fibrillation,
NSVT Non-sustained ventricular
tachyarrhythmias, SCD Sudden
cardiac death)
• Prevalence ~75%
• LVOTO in 70% of all cases
• LVEF >65%
• Diastole 0-1
• LA dilatation mild/moderate
• LGE <5%
• AF and NSVT rare
• SCD 0.5 – 1%
STAGE II ‘classic’ phenotype
STAGE I Non-hypertrophic
G+/Ph- (i.e. mutation carriers)
STAGE III
Adverse remodeling
STAGE IV 
Overt dysfunction
• Prevalence ~5-10%
• Systolic dysfunction
LVEF < 50%
• Diastole 2-3
• LA dilatation severe
• LGE >25%
• AF and NSVT very common
• SCD 10%
Reported changes in cardiac 
function (studies in human and 
animal models of HCM)
• Diastolic dysfunction
• Energetic changes
• Prevalence ~15%
• LVOTO not common
• LVEF 50-65%
• Diastole 2-3
• LA dilatation moderate/severe
• LGE 10-15%
• AF and NSVT common
Targets for therapy
Low force generating capacity
Increased sensitivity to calcium
Altered energetics
Altered cellular electrophysiology
Fibrosis
G+/Ph- Stage II
Stable G+/Ph-
a
b
phenotype-negative (G+/Ph–) individuals, i. e. of potential
patients.
Advancing core clinical knowledge of HCM in the clini-
cal community is important. The epidemiological relevance
of HCM, its clinical heterogeneity and complex pathophys-
iology emphasise the need to regularly update clinicians
on advances in basic and clinical research. Cardiologists
are often capable of recognising and managing the clas-
sic manifestations of disease, but knowledge of the risk
of disease progression and identification of the less typi-
cal (and less favourable) manifestations as HCM may be
limited. As each clinical stage of HCM requires a different
treatment strategy, recognising HCM at any given stage is
critical for appropriate management and family screening.
To accurately monitor disease progression and prescribe
appropriate drug treatment, it is important to be aware of
the changes that may occur during the different stages of
disease development (Fig. 1a; [5]).
Stages of HCM
As with any biological process or disease, HCM is a contin-
uum. Any attempt to identify stages must thus be considered
an oversimplification of countless exceptions and nuances
present in the clinical spectrum. However, the following
conceptual framework constitutes a clinically useful aid to
understanding the long-term course of HCM and its com-
plications, exemplified by the two cases presented below.
Stage I – genotype-positive, phenotype-negative
individuals
The status of G+/Ph– individuals, identified during family
screening, is defined as Stage I (Fig. 1a). This group rep-
resents a major challenge, as based on past experience we
now know that the same mutation will cause cardiomyopa-
thy in one individual but may be harmless in a direct family
member. Although LV hypertrophy – the hallmark of HCM
– is absent, advanced echocardiographic characterisation,
including tissue Doppler and strain imaging, reveals initial
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diastolic dysfunction and increased left atrial (LA) dimen-
sion in G+/Ph– individuals [6, 7]. Cardiac magnetic imag-
ing (CMR) studies may show ancillary signs such as crypts,
papillary muscle abnormalities and septo-apical bundles
[8]. Current guidelines recommend long-term evaluation of
G+/Ph– individuals with echocardiography and electrocar-
diography (ECG) [1], although, as indicated above, follow-
up studies show development of LV hypertrophy only in
a minority [9]. In the event of an abnormal ECG, it is ad-
visable to perform CMR imaging, as apical or anterolateral
hypertrophy may be missed on echocardiography and some
individuals may present without hypertrophy but evidence
of late gadolinium enhancement (LGE).
The recommended interval for follow-up clinical eval-
uations differs between guidelines; the American College
of Cardiology Foundation/American Heart Association
(ACCF/AHA) recommends screening every 12–18 months
from age 12 to 18–21 years and at least every 5 years above
the age of 21 [10]. The European Society of Cardiology
(ESC) guidelines advise follow-up, but do not recommend
a specific interval [1]. The proportion of G+/Ph– indi-
viduals that will develop overt disease is still uncertain.
The likelihood of this increases with age, but conversion
seems to be slow, both in children and adults [11, 12]. We
currently see G+/Ph– individuals at 2-year intervals when
they have ECG and echocardiography. It is important to
emphasise that the threshold to diagnose HCM in a first-
degree relative of a proband or G+/Ph– individuals is less
stringent than classic diagnostic criteria for novel patients,
i. e. a maximal wall thickness (MWT) ≥ 13 mm is consid-
ered sufficient. SCD is extremely rare in the absence of LV
hypertrophy, but has been described in isolated cases [13,
14]. In G+/Ph– individuals with a family history indicating
a high SCD risk, periodic assessment of arrhythmias by
means of exercise testing and Holter monitoring may be
appropriate.
Stage II – classic phenotype
Most HCM patients will present in stage II disease, the
classic phenotype defined in the majority of patients by the
presence of LV hypertrophy, normal or supernormal sys-
tolic function and LV outflow tract obstruction (LVOTO)
at rest or during provocation (Fig. 1a). At this stage ther-
apy is mainly determined by the presence and severity of
symptoms associated with LVOTO or arrhythmias. For the
management of symptoms and the assessment of SCD risk it
is important to actively search for LVOTO in HCM patients
without obstruction at baseline. Routine echocardiography
should therefore include the Valsalva manoeuvre, and ex-
ercise echocardiography is recommended in symptomatic
patients who are non-obstructive at rest [1].
Clinical and echocardiographic follow-up every 1–2 years
is advised for asymptomatic HCM patients with maximum
provoked peak LVOTO < 50 mm Hg, depending on the
general context and associated risk factors. Current guide-
lines do not recommend aggressive treatment for patients
with obstructive HCM who are asymptomatic. However,
medical therapy is often prescribed for gradient control,
particularly in active individuals. In symptomatic patients
with LVOTO ≥ 50 mm Hg, the first step is medical therapy
with non-vasodilating beta blockers. Verapamil can be used
as an alternative for patients who are intolerant or have
contraindications to beta blockers. Disopyramide is recom-
mended in addition to beta blockers to improve symptoms.
Invasive treatment (surgical myectomy or septal alcohol ab-
lation) to reduce LVOTO is indicated in HCM patients who
remain in NYHA Class III–IV with LVOTO ≥ 50 mm Hg
despite optimal medical therapy. Surgeons and cardiologists
who perform invasive treatment in HCM should work as
part of a focused multidisciplinary team in order to choose
the best treatment option. Symptomatic patients who are
non-obstructive at rest or on provocation are treated with
beta blockers, verapamil or diltiazem to control the heart
rate. Judicious use of loop diuretics may be considered to
reduce LV diastolic and pulmonary pressures.
In all HCM patients, the estimation of SCD risk is part of
clinical management and should be re-evaluated at 1–2 year
intervals or when there is a change in clinical status. Risk
assessment should include clinical and family history, 48-
hour ambulatory ECG, echocardiography and an exercise
test. The exact value of CMR in the prediction of the SCD
risk still needs to be determined. There is universal agree-
ment on the indication for an implantable cardioverter defib-
rillator (ICD) for secondary prevention in cardiac arrest sur-
vivors. With regard to primary prevention, the approaches
in Europe and the United States differ and the issue is cur-
rently a subject of debate. The recent ESC guidelines pro-
pose the use of a novel HCM SCD score, advising consider-
ing an ICD when the estimated 5-year SCD risk exceeds 6%
[1]. This score is currently being validated in independent
cohorts, with somewhat conflicting results [15, 16]. The
ACCF/AHA guidelines favour individual, non-parametric
evaluation of major risk factors (family history of SCD,
MWT ≥ 30 mm, syncope, presence of non-stained ventric-
ular tachycardia on Holter monitoring and abnormal blood
pressure response on exercise), and advise an ICD for pri-
mary prevention in the presence of ≥1 risk factor (family
history of SCD, syncope or MWT ≥ 30 mm) or ≥2 risk
factors [17].
Since HCM is an inherited disease, genetic testing is
indicated to enable family screening by pre-symptomatic
DNA testing. All HCM patients should be referred to a car-
dio-genetic centre, where cardiologists and clinical geneti-
cists work in close collaboration and genetic testing is per-
Houten 2017
Advertisement placed here.
Houten 2017
Advertisement placed here.
Houten 2017
Advertisement placed here.
Houten 2017
Advertisement placed here.
Neth Heart J (2017) 25:186–199 193
formed after comprehensive clinical phenotyping and coun-
selling. Following the identification of a pathogenic muta-
tion, genetic testing can be offered to identify family mem-
bers at risk for disease. In HCM patients in whom DNA
testing is inconclusive, first-degree family members should
be offered cardiological screening by ECG and echocardio-
graphy. Before family members undergo clinical or genetic
testing they should be counselled by a clinical geneticist
to make sure they understand the possible consequences of
testing.
Stage III – adverse remodelling
In stage III, HCM is characterised by a gradual decrease
of LV ejection fraction (LVEF), progression of diastolic
dysfunction and LA dilatation, often with and the disap-
pearance of LVOTO (Fig. 1a). A CMR-derived LVEF of
50–65% may already be associated with significant de-
grees of myocardial fibrosis, suggesting that progression
to end-stage disease has begun. In the presence of conges-
tive symptoms or increased filling pressures, standard HF
therapy with diuretics, beta blockers, angiotensin convert-
ing enzyme (ACE) inhibitors, angiotensin receptor blockers
(ARBs) and mineralocorticoid receptor antagonists (MRAs)
may be considered. The presence of extensive LGE is im-
portant as it lowers the threshold for decision-making re-
garding ICD implantation [18]. At this stage, atrial fibril-
lation (AF) begins to emerge as the leading management
challenge. AF is the most frequent arrhythmia in HCM, af-
fecting more than 20% of patients. It not only worsens the
symptoms of HF, but is also a marker of an unfavourable
prognosis. All HCM patients with AF have an indication for
oral anticoagulation, irrespective of the CHA2DS2-VASc
score [19].
Stage IV – overt dysfunction
Patients in whom the process of adverse remodelling pro-
ceeds further ultimately reach stage IV, in which the LVEF
may drop below 50% and LV diastolic dysfunction is al-
ways severe, generally causing HF [19]. At this stage ther-
apy with diuretics, beta blockers, ACE inhibitors, ARBs and
MRAs in accordance with the ESC guidelines for the man-
agement of chronic HF is indicated. Progression to end-
stage disease with systolic dysfunction is associated with
a high risk of SCD and is an indication for ICD implanta-
tion [10, 19]. When HF becomes severe, referral to heart
transplantation centres should be considered, irrespective
of LVEF values, before refractory pulmonary hypertension
occurs. Heart transplant in HCM candidates has an excel-
lent prognosis. The use of LV-assist devices is possible but
may be challenging due to small LV cavity dimensions, as
HCM progression is more often hypokinetic-restrictive than
hypokinetic-dilated.
Genetic testing in HCM
Since the identification of the first HCM mutation in 1989,
over 1500 pathogenic mutations in at least 11 genes encod-
ing thick and thin myofilament protein components of the
sarcomere have been identified [20]. A pathogenic mutation
is found in about 50% of HCM patients [3]. In the Nether-
lands, three MYBPC3 founder mutations (c.2373dupG,
c.2827C > T, and c.2864_2865delCT) account for 35% of
HCM cases [21]. Currently, the main clinical advantage
of genotyping HCM patients is enabling family screening.
The prognostic significance of genetic testing in individual
HCM patients is less clear. Studies comparing genotype-
positive and genotype-negative HCM patients have shown
a favourable outcome for genotype-negative HCM patients
[22–25]. The presence of double or compound sarcomere
gene mutations in a patient is associated with earlier disease
onset and more severe outcome [26].
Lifestyle advice
As a general rule, conditions that reduce circulating blood
volume should be avoided to prevent worsening of obstruc-
tion in the event of fever, diarrhoea and dehydration. Advice
regarding an appropriate lifestyle may be extremely useful
in reducing symptoms and risk in HCM patients, and may
suffice in milder forms of the disease in which pharmaco-
logical therapy is not warranted. There is general consensus
that patients should abstain from competitive sports, as well
as from strenuous and protracted physical activities which
can trigger arrhythmias and SCD (Class I, Class of recom-
mendation in the 2014 ESC guidelines) [1]. The advisable
level of exercise may be evaluated on an individual basis
by exercise echocardiography. Sporting activities should
be pulsemeter-guided, with pre-specified maximum heart
rates, allowing preference for endurance over stop-and-go
disciplines or contact sports. Pregnancy is well tolerated in
most HCM patients. However, adequate counselling should
be provided and management should follow the 2011 ESC
guidelines on the management of cardiovascular diseases
during pregnancy. Similar considerations apply to non-car-
diac surgery and invasive procedures in accordance with
2014 ESC/European Society Anaesthesiology (ESA) guide-
lines on non-cardiac surgery [27].
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Fig. 2 Progression of disease in patient case 1. a Progressive increase in cardiac dimensions, b a rise and subsequent decline in LVOTO, c a gradual
decrease in MWT and d LV ejection fraction, e the different disease stages of the patient (LA Left atrium, LVESD Left ventricular end-systolic
dimensions, LVEDD Left ventricular end-diastolic dimensions, LVOTO LV outflow tract obstruction, MWT Maximal wall thickness, LVEF LV
ejection fraction [LVEF])
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Fig. 3 Echocardiographic follow-up of case 1. Transthoracic echocardiogram of case 1 in 2005 (a–c) and 2015 (d–f). During 10 years of follow-up
there was a gradual decrease of septal (*) and left ventricular posterior wall () thickness and an increase of left ventricular dimension (●)
Changing scenarios: a history of two patients
The difficulty of accurately managing the diverse paths that
an HCM patient may travel is illustrated by the following
case histories.
Case 1
The first patient is a 33-year-old man (Figs. 2 and 3). He
was first seen at the age of 12 after he turned pale during
exercise, but did not collapse. His family history was pos-
itive for HCM and SCD; his mother died at the age of 33.
At that time, he was diagnosed with HCM following de-
tection of asymmetrical LV hypertrophy and an MWT of
33 mm with normal systolic function; he had no LVOT gra-
dient at rest or during the Valsalva manoeuvre. However, at
the age of 13 a severe gradient of 85 mm Hg was noted on
Valsalva (Fig. 2b). At this time he was clearly in stage II.
Because of the absence of severe symptoms and his very
young age, a conservative strategy was chosen and follow-
up was performed at a peripheral hospital.
At the age of 23, he was referred to the HCM outpatient
clinic of the Erasmus Medical Center with palpitations and
syncope. At that time his echocardiogram showed an MWT
of 30 mm, with normal systolic function and absence of
LVOTO. Based on the presence of a positive family history
for SCD, massive hypertrophy and syncope, he received
an ICD for primary prevention of SCD. At the age of 28
he experienced his first appropriate ICD shock due to fast
ventricular tachycardia (VT) at 214/min. At age 30 genetic
testing revealed a pathogenic missense mutation in myosin
heavy chain (MYH7;c.3133C > T;p.Arg1045Cys). At age 32
he experienced inappropriate ICD shocks caused by an iso-
lation defect of the ICD lead, which was then replaced. At
age 33 he experienced two further appropriate ICD shocks
for fast VT.
Over 20 years of echocardiographic follow-up there was
a gradual decrease in MWT, LVEF and LVOT gradient, and
a gradual increase in LA diameter, LV end-diastolic dimen-
sion and LV end-systolic dimension (Figs. 2 and 3), sug-
gesting progression from stage II to stage III. At age 33 the
patient experienced his first episode of fluid retention lead-
ing to congestive HF. His LVEF is currently 25% and he is
on a regimen of beta blockers, ACE inhibitors, loop diuret-
ics, MRAs and amiodarone. He is in stage IV and NYHA
class III, without signs of fluid retention, and has been re-
ferred to the cardiac transplantation programme. Thus far
there have been no episodes of AF.
Case 2
The second patient is a 60-year-old woman, in whom mild
asymmetrical hypertrophy was observed during a routine
occupational check-up at age 39 (Fig. 4). Echocardiogra-
phy showed a high LVEF (78%) and an MWT of 20 mm
(stage II). She was followed-up yearly at a peripheral hos-
pital. Echocardiography showed no LVOTO at rest, and
provocation with Valsalva or exercise was never performed.
Treatment with disopyramide and verapamil was started.
From the age of 46 she had experienced recurrent chest
pain. At age 50 the LV anterior wall was described as aki-
netic (stage II–III), and over subsequent years there was
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Fig. 4 Progression of disease in patient case 1. a Progressive increase in cardiac dimensions (LA Left atrium, LVESD and LVEDD Left ventricular
end-systolic and end-diastolic dimensions), b decline in maximal wall thickness (MWT) and c a decline in LV ejection fraction (LVEF). d The
different disease stages of the patient. e Cardio magnetic imaging at stage IV of the disease showing a dilated heart and extensive late gadolinium
enhancement (arrow)
a gradual decrease of LVEF coupled with progressive di-
latation of the LV and LA (stage III). At age 58 the pa-
tient was admitted to the emergency department with AF
and a coronary angiogram was performed which excluded
coronary artery disease as the cause of LVEF deterioration.
At age 58 the patient was seen at the outpatient clinic of
the UMC Utrecht. CMR showed an LVEF of 32% and ex-
tensive LGE (Fig. 4e), suggesting replacement fibrosis and
stage IV disease. Genetic testing identified a pathogenic
splice-site mutation in the gene encoding myosin-binding
protein C (MYBPC3; c.654 + 1G > A). This led to the
conclusion that the patient had HCM, with LV dysfunction
in the context of end-stage progression. The diagnosis was
supported by residual mild, but significant LV hypertrophy
(MWT 13 mm). The pattern of LGE together with a history
of angina supported the presence of progressive ischaemic
damage caused by microvascular dysfunction [28, 29] lead-
ing to replacement fibrosis.
These two cases illustrate how individual patients may
progress through different stages of HCM during their life-
time, with profoundly different clinical profiles, risks and
therapeutic needs. Unless all these stages are familiar to car-
diologists, there is a substantial possibility that the disease
will be misinterpreted and mismanaged over time.
Optimal organisation for HCM patient care
Although HCM is the most common inherited cardiac dis-
ease, it is uncommon when compared with conditions such
as coronary artery or valvular disease, and its devastat-
ing complications such as SCD and end-stage progression
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are rare. Fortunately, the majority of HCM patients have
a favourable prognosis and a stable course. One of the
major challenges in HCM care is the identification of pa-
tients at high risk for adverse outcome. During follow-up,
special attention should be paid to so-called red flags of
progression, reduction of LV function, LA dilatation, re-
duction of MWT and onset of AF. In addition, risk strat-
ification for SCD should be performed periodically. HCM
care needs close collaboration between cardiologists, clin-
ical geneticists, thoracic surgeons, interventional cardiolo-
gists and electrophysiologists [30].
Decisions on when and how to intervene should be made
at a centre with specific expertise in HCM care. A dedi-
cated HCM heart team is critical in the interest of patients
and their families. General cardiologists not specifically
involved in HCM care should become familiar with the
main issues such as identification of high-risk profiles and
clinical screening of HCM families. However, they should
closely liaise with experienced HCM centres whenever the
diagnosis is uncertain, the symptoms are hard to explain
and/or do not adequately respond to medical treatment, and
when genetic counselling is required. Furthermore, periph-
eral centres should always seek advice from an HCM team
when a major clinical decision (such as performing septal
reduction therapy or implanting an ICD) is being consid-
ered. Finally, referral is mandatory for patients in Stage IV
with severe HF symptoms, for timely consideration of heart
transplantation. Because the end stage of HCM is charac-
terised by a relatively preserved LVEF on comparison with
classic models of HF, the severity of disease may be un-
derestimated until transplant is no longer feasible due to
refractory pulmonary hypertension. A particularly challeng-
ing group is the subset of patients identified in the paediatric
age range, for whom specific HCM diagnostic criteria ex-
ist – but are not validated – and management options are
poorly, if at all, supported by evidence [1]. Because of the
complexity of genetic testing and the possible social and
financial consequences, all patients and family members
should be counselled before undergoing genetic testing.
Genetic testing is done at cardio-genetic outpatient clin-
ics, where clinical geneticists, genetic counsellors, social
workers and cardiologists closely collaborate. Being part
of an extended network revolving around HCM centres is
the best guarantee for practising cardiologists and their pa-
tients, by promoting awareness and close interaction with
multidisciplinary experts.
Future perspectives in HCM research
The sequence and causality of the pathomechanisms that
initiate and exacerbate HCM are unknown, and current
treatment options are insufficient to prevent the disease.
Longitudinal studies of in vivo cardiac function and in vitro
studies (muscle preparations, HCM mouse models) are
needed to elucidate the pathogenesis of HCM and identify
novel drug targets (Fig. 1b). In the early stage of the dis-
ease (stage I), deficits are seen in energetic status of the
heart, reflected by a reduced phosphocreatine/ATP ratio
and reduced myocardial efficiency [31–33]. Moreover, Ho
and colleagues [34] detected early pro-fibrotic signalling
in patients with thick filament mutations before the onset
of hypertrophy or detectable fibrosis on CMR. Thus, while
mutation carriers (stage I) do not exhibit symptoms and do
not show LV hypertrophy, the intrinsic properties of their
heart muscle clearly differ from a healthy control popula-
tion. Recent studies in human cardiac muscle revealed high
sensitivity to calcium of the sarcomeres, which may under-
lie arrhythmias [35, 36], reduced contractile performance
of single cardiomyocytes [37] and high energetic costs for
muscle contraction [33]. These cellular pathomechanisms
should be further explored [38, 39], and interventions aim-
ing to correct these cellular deficits should be tested in
an experimental setting (animal models). Such treatments
include gene correction, and therapies targeting sarcomere
function, ion channels or metabolism [40]. Subsequently,
clinical trials are needed to build proof for novel preven-
tive treatment strategies. Based on positive effects of the
L-type Ca2+ channel blocker diltiazem in mouse models of
HCM, a clinical pilot study was performed in G+/Ph– in-
dividuals [41]. This double-blind, randomised, placebo-
controlled clinical trial proved that preclinical treatment
with diltiazem is safe and feasible and revealed that the
drug treatment has a positive effect. Diltiazem prevented
the progressive reduction in LV cavity size characteristic
of HCM development. The improvement was lost within
a year after treatment was interrupted. This study illustrates
the strength of a well-designed clinical trial in G+/Ph– in-
dividuals. In order to further unravel the pathomechanisms
of HCM, basic scientists and clinical cardiologists should
work together with their ultimate goal being the develop-
ment of a curative treatment of this common disease.
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